Public Willingness to Undergo Presymptomatic Genetic Testing for Alzheimer's Disease.

IF 1.7 Q4 NEUROSCIENCES Neurology Research International Pub Date : 2019-03-03 eCollection Date: 2019-01-01 DOI:10.1155/2019/2570513
Mohammed H Alanazy, Khalid A Alghsoon, Abdulaziz F Alkhodairi, Faisal K Binkhonain, Turkey N Alsehli, Feras F Altukhaim, Ibrahim M Alkhodair, Taim Muayqil
{"title":"Public Willingness to Undergo Presymptomatic Genetic Testing for Alzheimer's Disease.","authors":"Mohammed H Alanazy,&nbsp;Khalid A Alghsoon,&nbsp;Abdulaziz F Alkhodairi,&nbsp;Faisal K Binkhonain,&nbsp;Turkey N Alsehli,&nbsp;Feras F Altukhaim,&nbsp;Ibrahim M Alkhodair,&nbsp;Taim Muayqil","doi":"10.1155/2019/2570513","DOIUrl":null,"url":null,"abstract":"<p><p>Presymptomatic genetic testing (PGT) for Alzheimer's disease (AD) is available for at-risk individuals. This study aimed to investigate the public perception of PGT in Saudi Arabia and determine variables that might influence the decision to undergo PGT. A questionnaire link was posted on Twitter by the Saudi Alzheimer's Disease Association and was made publicly available on social media networks. A total of 2935 people participated, of which 59.9% were willing to undergo PGT. Of these, 26.8% reported having a family history of AD, and 0.24% had two family members with early onset AD. The reasons cited for willingness to undergo PGT included the following: to adopt a healthier lifestyle, to ensure appropriate family and financial planning, to seek early treatment, and to relieve anxiety. In multiple logistic regression analysis, willingness to undergo PGT was negatively associated with having a self-reported family history of dementia (OR 0.81, 95% CI 0.68-0.96) and was positively associated with marital status (OR 1.39, 95% CI 1.13-1.70). In conclusion, PGT for AD seems to be well accepted in this large Saudi cohort. The reasons cited are similar to those reported elsewhere in the literature.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2019-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/2570513","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology Research International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2019/2570513","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 4

Abstract

Presymptomatic genetic testing (PGT) for Alzheimer's disease (AD) is available for at-risk individuals. This study aimed to investigate the public perception of PGT in Saudi Arabia and determine variables that might influence the decision to undergo PGT. A questionnaire link was posted on Twitter by the Saudi Alzheimer's Disease Association and was made publicly available on social media networks. A total of 2935 people participated, of which 59.9% were willing to undergo PGT. Of these, 26.8% reported having a family history of AD, and 0.24% had two family members with early onset AD. The reasons cited for willingness to undergo PGT included the following: to adopt a healthier lifestyle, to ensure appropriate family and financial planning, to seek early treatment, and to relieve anxiety. In multiple logistic regression analysis, willingness to undergo PGT was negatively associated with having a self-reported family history of dementia (OR 0.81, 95% CI 0.68-0.96) and was positively associated with marital status (OR 1.39, 95% CI 1.13-1.70). In conclusion, PGT for AD seems to be well accepted in this large Saudi cohort. The reasons cited are similar to those reported elsewhere in the literature.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
公众愿意接受阿尔茨海默病症状前基因检测。
阿尔茨海默病(AD)的症状前基因检测(PGT)可用于高危人群。本研究旨在调查沙特阿拉伯公众对PGT的看法,并确定可能影响接受PGT决定的变量。沙特阿尔茨海默病协会在推特上发布了一份问卷链接,并在社交媒体网络上公开发布。共有2935人参与,其中59.9%的人愿意接受PGT。其中,26.8%的人报告有AD家族史,0.24%的人有两个家族成员患有早发性AD。愿意接受PGT的原因包括:采取更健康的生活方式,确保适当的家庭和财务规划,寻求早期治疗,以及缓解焦虑。在多元logistic回归分析中,接受PGT的意愿与自我报告的痴呆家族史呈负相关(OR 0.81, 95% CI 0.68-0.96),与婚姻状况呈正相关(OR 1.39, 95% CI 1.13-1.70)。总之,在这个庞大的沙特人群中,PGT治疗AD似乎得到了很好的接受。引用的原因与文献中其他地方的报道相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
10
审稿时长
17 weeks
期刊介绍: Neurology Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focusing on diseases of the nervous system, as well as normal neurological functioning. The journal will consider basic, translational, and clinical research, including animal models and clinical trials.
期刊最新文献
Increased Cerebrospinal Fluid Adenosine 5'-Triphosphate Levels in Patients with Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy. Glucometabolic-Related Genes as Diagnostic Biomarkers and Therapeutic Targets for Alzheimer's Disease and Type 2 Diabetes Mellitus: A Bioinformatics Analysis Sleep Disorders and Fatigue among Patients with MS: The Role of Depression, Stress, and Anxiety. Neuroprotective Effects of Rosa damascena Extract against Aluminum Chloride-Induced Brain Damage in Rat Offspring Serum Level of Brain-Derived Neurotrophic Factor and Thrombotic Type Are Predictive of Cognitive Impairment in the Acute Period of Ischemic Strokes Patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1